Logo Logo
Switch Language to German

Blaschek, Astrid; Vill, Katharina; Müller-Felber, Wolfgang and Schara, Ulrike (2020): Molekulare Therapien bei neuromuskulären Erkrankungen im Kindesalter — Große Hoffnungen und unbekannte Risiken. In: Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, Vol. 63, No. 7: pp. 891-897 [PDF, 735kB]


Spinal muscular atrophy and muscular dystrophy Duchenne belong to the group of rare neuromuscular diseases manifesting in early childhood. Therapeutic options for some of these rare monogenic diseases have changed significantly in recent years. Molecular therapies such as direct gene transfer or alternative processing of the disease-specific gene play an important role in this transformation.In particular, the course of 5q-associated spinal muscle atrophy has changed significantly due to the availability of such causal therapies, while the results of ongoing studies are still pending for most muscle diseases. In the area of neuromuscular diseases, an achievable therapeutic goal is to slow the progression, but not complete healing. Currently, only limited data are available. In particular, the long-term effectiveness and the possible risks are still unknown. Therefore, these therapies should be used under strictly monitored conditions.

Actions (login required)

View Item View Item